BRD4 is a novel therapeutic target for liver fibrosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 51, 2015, Pages 15713-15718

  Ding, Ning ^a   Hah, Nasun ^a   Yu, Ruth T ^a   Sherman, Mara H ^a   Benner, Chris ^a   Leblanc, Mathias ^a   He, Mingxiao ^a   Liddle, Christopher ^b   Downes, Michael ^a   Evans, Ronald M ^a,c  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Antifibrotic therapy; BET inhibitor; BRD4; Hepatic stellate cell; Liver fibrosis

Indexed keywords

2 METHOXY N (1,2,3,4 TETRAHYDRO 3 METHYL 2 OXO 6 QUINAZOLINYL)BENZENESULFONAMIDE; 4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 7 (3,5 DIMETHYL 4 ISOXAZOLYL) 1,3 DIHYDRO 8 METHOXY 1 [1 (2 PYRIDINYL)ETHYL] 2H IMIDAZO[4,5 C]QUINOLIN 2 ONE; BROMODOMAIN CONTAINING PROTEIN 4; PROTEIN; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BRD4 PROTEIN, MOUSE; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CELL ACTIVATION; CONTROLLED STUDY; ENHANCER REGION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; INTERVENTION STUDY; INVESTIGATIVE PROCEDURES; LIVER FIBROSIS; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STELLATE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; HEPATIC STELLATE CELL; LIVER CIRRHOSIS, EXPERIMENTAL; PHYSIOLOGY;

ANIMALS; AZEPINES; CELLS, CULTURED; HEPATIC STELLATE CELLS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84952683263     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1522163112     Document Type: Article

References (25)

1. Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat Med 18(7):1028-1040.
2. Friedman SL, Sheppard D, Duffield JS, Violette S (2013) Therapy for fibrotic diseases: Nearing the starting line. Sci Transl Med 5(167):167sr1.
3. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214(2):199-210.
4. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115(2):209-218.
5. Friedman SL (2008) Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88(1):125-172.
6. Mederacke I, et al. (2013) Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 4:2823.
7. Ding N, et al. (2013) A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153(3):601-613.
8. Lee TI, Young RA (2013) Transcriptional regulation and its misregulation in disease. Cell 152(6):1237-1251.
9. Filippakopoulos P, et al. (2010) Selective inhibition of BET bromodomains. Nature 468(7327):1067-1073.
10. Xu L, et al. (2005) Human hepatic stellate cell lines, LX-1 and LX-2: New tools for analysis of hepatic fibrosis. Gut 54(1):142-151.
11. Dawson MA, et al. (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478(7370):529-533.
12. Nicodeme E, et al. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468(7327):1119-1123.
13. Fish PV, et al. (2012) Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem 55(22):9831-9837.
14. Trojanowska M (2000) Ets factors and regulation of the extracellular matrix. Oncogene 19(55):6464-6471.
15. Small EM (2012) The actin-MRTF-SRF gene regulatory axis and myofibroblast differentiation. J Cardiovasc Transl Res 5(6):794-804.
16. Seki E, et al. (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13(11):1324-1332.
17. Hernandez-Gea V, Friedman SL (2011) Pathogenesis of liver fibrosis. Annu Rev Pathol 6:425-456.
18. Bachem MG, Meyer D, Melchior R, Sell KM, Gressner AM (1992) Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblastlike cells. A potential mechanism of self perpetuation in liver fibrogenesis. J Clin Invest 89(1):19-27.
19. Friedman SL, Roll FJ, Boyles J, Arenson DM, Bissell DM (1989) Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. J Biol Chem 264(18):10756-10762.
20. Geerts A, et al. (1989) In vitro differentiation of fat-storing cells parallels marked increase of collagen synthesis and secretion. J Hepatol 9(1):59-68.
21. Wong L, Yamasaki G, Johnson RJ, Friedman SL (1994) Induction of beta-plateletderived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 94(4):1563-1569.
22. Chen H, et al. (2011) PDGF signalling controls age-dependent proliferation in pancreatic β-cells. Nature 478(7369):349-355.
23. Dobin A, et al. (2013) STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15-21.
24. Trapnell C, et al. (2013) Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol 31(1):46-53.
25. Barish GD, et al. (2010) Bcl-6 and NF-kappaB cistromes mediate opposing regulation of the innate immune response. Genes Dev 24(24):2760-2765.